Investigating a new RNA therapy to reduce bleeding by controlling fibrinolysis
Official title: Understanding and Controlling the Contribution of Fibrinolysis to Bleeding Using a Long-Acting Antifibrinolytic RNA Therapy
Funded at Versiti Wisconsin, INC. · NIH-10907802 · Data updated 2026-11-12
This study is looking at how a process that breaks down blood clots can lead to too much bleeding in people with bleeding disorders, and it aims to help these patients by using special RNA treatments that could make bleeding easier to manage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Wisconsin, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $707,172 |
| NIH project number | 5R01HL166382-02 |
| Project ID | NIH-10907802 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with diagnosed or undiagnosed bleeding disorders who experience acute bleeding episodes.
✕Less likely to help
Patients who do not have bleeding disorders or those whose bleeding is not related to fibrinolysis may not benefit from this research.
What this research studies
This research focuses on understanding how fibrinolysis, the process that breaks down blood clots, contributes to excessive bleeding in patients with bleeding disorders. The team hypothesizes that by using long-acting RNA therapies that target plasminogen, they can effectively reduce fibrinolysis and improve bleeding management. The approach involves delivering these RNA agents through lipid nanoparticles, which are already approved for clinical use. This innovative method aims to provide a long-term solution for patients suffering from various bleeding disorders.
Why it matters
Potential benefit: If successful, this research could lead to more effective long-term treatments for patients with bleeding disorders, reducing the incidence and severity of bleeding episodes.
How similar studies have gone: While the approach of using RNA therapies is innovative, similar strategies targeting coagulation processes have shown promise in other studies, indicating potential for success.
Where this research is happening
-
Versiti Wisconsin, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Kastrup, Christian — Versiti Wisconsin, INC.
- Study coordinator: Kastrup, Christian
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Long-acting RNA therapy to control fibrinolysis and reduce bleeding
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.